journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/28920766/clinical-profile-of-patients-with-paraneoplastic-neuromyelitis-optica-spectrum-disorder-and-aquaporin-4-antibodies
#1
Maria Sepúlveda, Nuria Sola-Valls, Domingo Escudero, Bojan Rojc, Manuel Barón, Luis Hernández-Echebarría, Begoña Gómez, Josep Dalmau, Albert Saiz, Francesc Graus
BACKGROUND: In a minority of patients with neuromyelitis optica spectrum disorder (NMOSD) and aquaporin-4 antibodies (AQP4-IgG), the disease has a paraneoplastic origin. It is unknown whether these patients have distinctive clinical features. OBJECTIVE: To report the clinical features of a series of patients with paraneoplastic NMOSD and AQP4-IgG and to review previously reported cases. METHODS: Retrospective analysis of clinical records of 156 patients with NMOSD and AQP4-IgG and review of previously reported patients with paraneoplastic NMOSD and AQP4-IgG...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28920765/medication-usage-and-falls-in-people-with-multiple-sclerosis
#2
Laura Comber, Gillian Quinn, Chris McGuigan, Rose Galvin, Susan Coote
There is a need to identify modifiable risk factors for falls in people with multiple sclerosis (MS) to enable the design of successful falls prevention interventions. There is conflicting evidence regarding the association between medication use and occurrence of falls in MS. A total of 101 people with MS had medications classified using the Anatomical Therapeutic Classification system and number of falls prospectively monitored for 3 months. No association was noted between number of medications and falls...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28920764/recurrence-of-disease-activity-during-pregnancy-after-cessation-of-fingolimod-in-multiple-sclerosis
#3
Ingrid Meinl, Joachim Havla, Reinhard Hohlfeld, Tania Kümpfel
BACKGROUND: Fingolimod is an effective treatment for active relapsing-remitting multiple sclerosis (MS). Discontinuation of therapy may be followed by recurrence of disease activity. Thus, female MS patients may be at risk of relapse during pregnancy after stopping fingolimod. OBJECTIVES AND METHODS: To report the disease course during pregnancy of five women who interrupted therapy with fingolimod for pregnancy. RESULTS: All patients experienced relapses during pregnancy and/or postpartum after stopping fingolimod...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28914581/circulating-lymphocyte-levels-and-relationship-with-infection-status-in-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-daclizumab-beta
#4
Gavin Giovannoni, Heinz Wiendl, Benjamin Turner, Kimberly Umans, Oksana Mokliatchouk, Wanda Castro-Borrero, Steven J Greenberg, Peter McCroskery, Giorgio Giannattasio
BACKGROUND: Reversible lymphocyte count reductions have occurred following daclizumab beta treatment for relapsing-remitting multiple sclerosis. OBJECTIVE: To analyse total and differential lymphocyte levels and relationship with infection status. METHODS: In DECIDE, blood samples were collected at 12-week intervals from daclizumab beta- ( n = 919) or intramuscular interferon beta-1a-treated ( n = 922) patients. Infections/serious infections were assessed proximate to grade 2/3 lymphopenia or low CD4(+)/CD8(+) T-cell counts...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28911260/two-year-results-from-a-phase-2-extension-study-of-oral-amiselimod-in-relapsing-multiple-sclerosis
#5
Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, A John Camm, Tobias Derfuss, Till Sprenger, Martin Davies, Alexandra Piotrowska, Pingping Ni, Tomohiko Harada
BACKGROUND: Amiselimod, an oral selective sphingosine-1-phosphate 1 receptor modulator, suppressed disease activity dose-dependently without clinically relevant bradyarrhythmia in a 24-week phase 2, placebo-controlled study in relapsing-remitting multiple sclerosis. OBJECTIVE: To assess safety and efficacy of amiselimod over 96 weeks. METHODS: After completing the core study, patients on amiselimod continued at the same dose, whereas those on placebo were randomised 1:1:1 to amiselimod 0...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28911257/fatigue-in-multiple-sclerosis-the-contribution-of-resting-state-functional-connectivity-reorganization
#6
Alvino Bisecco, Federica Di Nardo, Renato Docimo, Giuseppina Caiazzo, Alessandro d'Ambrosio, Simona Bonavita, Rocco Capuano, Leonardo Sinisi, Mario Cirillo, Fabrizio Esposito, Gioacchino Tedeschi, Antonio Gallo
OBJECTIVES: To investigate resting-state functional connectivity (RS-FC) of the default-mode network (DMN) and of sensorimotor network (SMN) network in relapsing remitting (RR) multiple sclerosis (MS) patients with fatigue (F) and without fatigue(NF). METHODS: In all, 59 RRMS patients and 29 healthy controls (HC) underwent magnetic resonance imaging (MRI) protocol including resting-state fMRI (RS-fMRI). Functional connectivity of the DMN and SMN was evaluated by independent component analysis (ICA)...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28906169/radiologically-isolated-syndrome-should-be-treated-with-disease-modifying-therapy-no
#7
Andrés Labiano-Fontcuberta, Julián Benito-León
No abstract text is available yet for this article.
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28906166/radiologically-isolated-syndrome-should-be-treated-with-disease-modifying-therapy-commentary
#8
Christine Lebrun
No abstract text is available yet for this article.
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28906165/radiologically-isolated-syndrome-should-be-treated-with-disease-modifying-therapy-yes
#9
Darin T Okuda
No abstract text is available yet for this article.
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28870107/safety-and-efficacy-of-cladribine-tablets-in-patients-with-relapsing-remitting-multiple-sclerosis-results-from-the-randomized-extension-trial-of-the-clarity-study
#10
Gavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Giancarlo Comi, Fernando Dangond, Abidemi K Adeniji, Patrick Vermersch
BACKGROUND: In the 2-year CLARITY study, cladribine tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing-remitting multiple sclerosis (MS). OBJECTIVE: To assess the safety and efficacy of cladribine treatment in a 2-year Extension study. METHODS: In this 2-year Extension study, placebo recipients from CLARITY received cladribine 3.5 mg/kg; cladribine recipients were re-randomized 2:1 to cladribine 3...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28859540/physician-assisted-death-should-be-available-to-people-with-ms-no
#11
Neil Scolding
No abstract text is available yet for this article.
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28859539/physician-assisted-death-should-be-available-to-people-with-ms-yes
#12
Kim Louise Wiebe
No abstract text is available yet for this article.
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28859536/physician-assisted-death-should-be-available-to-people-with-ms-commentary
#13
Alasdair Coles
No abstract text is available yet for this article.
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28857723/aquaporin-4-serostatus-does-not-predict-response-to-immunotherapy-in-neuromyelitis-optica-spectrum-disorders
#14
Maureen A Mealy, Su-Hyun Kim, Felix Schmidt, Reydmar López, Jorge A Jimenez Arango, Friedemann Paul, Dean M Wingerchuk, Benjamin M Greenberg, Ho Jin Kim, Michael Levy
BACKGROUND: Debate exists about whether neuromyelitis optica spectrum disorder seronegative disease represents the same immune-mediated attack on astrocytic aquaporin-4 as in seropositive disease. OBJECTIVE: We investigated whether response to common treatments for neuromyelitis optica spectrum disorder differed by serostatus, as assessed by change in annualized relapse rate. METHODS: We performed a multicenter retrospective analysis of 245 patients with neuromyelitis optica spectrum disorder who were treated with either rituximab or mycophenolate mofetil as their first-line immunosuppressive treatment for disease prevention...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28857721/unexpected-additive-effects-of-minocycline-and-hydroxychloroquine-in-models-of-multiple-sclerosis-prospective-combination-treatment-for-progressive-disease
#15
Simon Faissner, Yasamin Mahjoub, Manoj Mishra, Steffen Haupeltshofer, Jennifer Nancy Hahn, Ralf Gold, Marcus Koch, Luanne M Metz, Tamir Ben-Hur, V Wee Yong
BACKGROUND: Most multiple sclerosis (MS) patients succumb to a progressive phenotype. Continued lymphocyte activity in the brain, microglia-mediated injury, iron deposition, and oxidative stress are characteristics of progressive MS. OBJECTIVE: As minocycline and hydroxychloroquine have been shown to inhibit microglia, we evaluated their effects on other outcomes relevant for progression. METHODS: Medications were evaluated in culture and in mice with acute and chronic experimental autoimmune encephalomyelitis (EAE)...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28857686/natalizumab-during-pregnancy-and-lactation
#16
Undine Proschmann, Katja Thomas, Sandra Thiel, Kerstin Hellwig, Tjalf Ziemssen
BACKGROUND: Managing medication during pregnancy and lactation in multiple sclerosis (MS) patients needs to balance potential risks to the newborn with the substantial risks of ongoing disease activity. OBJECTIVE: To evaluate the potential transfer of natalizumab (NAT) into breast milk and into the serum of newborn babies in women who continued NAT treatment during pregnancy and lactation. METHODS: Serum samples of 11 mother-infant pairs and mother milk samples of a further 4 women were analyzed for free NAT using a HL60 cell-based fluorescence-activated cell sorting (FACS) assay...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28857680/cladribine-versus-fingolimod-natalizumab-and-interferon-%C3%AE-for-multiple-sclerosis
#17
Tomas Kalincik, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Jeannette Lechner-Scott, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Claudio Solaro, Francois Grand'Maison, Raymond Hupperts, Julie Prevost, Patrizia Sola, Diana Ferraro, Murat Terzi, Ernest Butler, Mark Slee, Allan Kermode, Marzena Fabis-Pedrini, Pamela McCombe, Michael Barnett, Cameron Shaw, Suzanne Hodgkinson, Helmut Butzkueven
OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. METHODS: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score-matched analyses compared treatment outcomes over 1 year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28847222/anti-jcv-serology-during-natalizumab-treatment-review-and-meta-analysis-of-17-independent-patient-cohorts-analyzing-anti-john-cunningham-polyoma-virus-sero-conversion-rates-under-natalizumab-treatment-and-differences-between-technical-and-biological-sero-converters
#18
Nicholas Schwab, Tilman Schneider-Hohendorf, Tammy Hoyt, Catharina C Gross, Sven G Meuth, Luisa Klotz, John F Foley, Heinz Wiendl
BACKGROUND: Anti-John Cunningham virus (JCV) serology has been studied with varying results concerning longitudinal changes. OBJECTIVES AND METHODS: Results from 17 published natalizumab-treated multiple sclerosis (MS) patient cohorts were analyzed with common parameters and subsequently verified in two large independent cohorts with 722 and 499 patients from Germany and the United States. RESULTS: Published studies and the verification showed (1) a mean of 10...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28847219/summit-serially-unified-multicenter-multiple-sclerosis-investigation-creating-a-repository-of-deeply-phenotyped-contemporary-multiple-sclerosis-cohorts
#19
Riley Bove, Tanuja Chitnis, Bruce Ac Cree, Mar Tintoré, Yvonne Naegelin, Bernard Mj Uitdehaag, Ludwig Kappos, Samia J Khoury, Xavier Montalban, Stephen L Hauser, Howard L Weiner
BACKGROUND: There is a pressing need for robust longitudinal cohort studies in the modern treatment era of multiple sclerosis. OBJECTIVE: Build a multiple sclerosis (MS) cohort repository to capture the variability of disability accumulation, as well as provide the depth of characterization (clinical, radiologic, genetic, biospecimens) required to adequately model and ultimately predict a patient's course. METHODS: Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) is an international multi-center, prospectively enrolled cohort with over a decade of comprehensive follow-up on more than 1000 patients from two large North American academic MS Centers (Brigham and Women's Hospital (Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB; BWH)) and University of California, San Francisco (Expression/genomics, Proteomics, Imaging, and Clinical (EPIC)))...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28831853/defining-active-progressive-multiple-sclerosis
#20
Finn Sellebjerg, Lars Börnsen, Cecilie Ammitzbøll, Jørgen Erik Nielsen, Tua Vinther-Jensen, Lena Elisabeth Hjermind, Marina von Essen, Rikke Lenhard Ratzer, Per Soelberg Sørensen, Jeppe Romme Christensen
BACKGROUND: It is unknown whether disease activity according to consensus criteria (magnetic resonance imaging activity or clinical relapses) associate with cerebrospinal fluid (CSF) changes in progressive multiple sclerosis (MS). OBJECTIVE: To compare CSF biomarkers in active and inactive progressive MS according to consensus criteria. METHODS: Neurofilament light chain (NFL), myelin basic protein (MBP), IgG-index, chitinase-3-like-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9), chemokine CXCL13, terminal complement complex, leukocyte counts and nitric oxide metabolites were measured in primary ( n = 26) and secondary progressive MS ( n = 26) and healthy controls ( n = 24)...
August 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"